Implementation of enhanced recovery after surgery in patients undergoing radical cystectomy: A retrospective cohort study.

e

Abstract:

BACKGROUND:To evaluate the feasibility and effect of implementing enhanced recovery after surgery (ERAS) in patients undergoing radical cystectomy (RC) and urinary diversion. MATERIALS AND METHODS:Since October 2016, a 15-point ERAS protocol has been implemented for patients undergoing elective RC and urinary diversion at Fudan University Shanghai Cancer Center (FUSCC). We retrospectively assessed patients who underwent RC performed between January 2014 and June 2018. The effects of implanting ERAS for RC were validated. RESULTS:A total of 443 patients were included. The ERAS and non-ERAS groups included 185 and 258 patients, respectively. There was no significant difference in the patients' demographic characteristics, operative variables, perioperative systemic inflammation-based scores or mortality rates. Compared with the non-ERAS group, our study showed decreases in intraoperative blood loss volumes and transfusion rates in the ERAS group. Patients in the ERAS group also had earlier times to tolerate a clean liquid diet intake, first ambulation and first flatus. The incidences of postoperative pneumonia, urine leakage, intestinal obstruction and deep venous thrombosis were also significantly lower in the ERAS group. The time to pelvic drainage tube removal and the length of stay (LOS) were significantly shorter in the ERAS group than in the non-ERAS group, and the ERAS group also had a significantly lower incidence of 30-day readmission. CONCLUSIONS:The results of this study suggest that ERAS protocols can accelerate the rehabilitation of patients undergoing RC, reduce the incidence of postoperative complications, shorten the LOS, and are safe and feasible in the field of RC. This study provides experience from FUSCC to further optimize ERAS protocols for patients with bladder cancer.

根治性膀胱切除术患者术后加速康复的实施: 一项回顾性队列研究。

c

摘要:

背景: 评估根治性膀胱切除术 (RC) 和尿流改道患者实施加速康复外科 (ERAS) 的可行性和效果。 材料和方法: 自 2016年10月以来,在复旦大学上海肿瘤中心 (FUSCC) 为择期 RC 和尿流改道患者实施了 15 点 ERAS 方案。我们回顾性评估了 2014年1月至 2018年6月期间接受 RC 的患者。验证了植入 ERAS 对 RC 的影响。 结果: 共纳入 443 例患者。ERAS 和非 ERAS 组分别包括 185 例和 258 例患者。患者的人口学特征、手术变量、围手术期全身炎症评分或死亡率无显著差异。与非 ERAS 组相比,我们的研究显示 ERAS 组术中失血量和输血率降低。ERAS 组患者也有更早的时间耐受清洁液体饮食摄入、首次下床活动和首次排气。ERAS 组术后肺炎、尿漏、肠梗阻和深静脉血栓形成的发生率也显著降低。ERAS 组的盆腔引流管拔除时间和住院时间 (LOS) 显著短于非 ERAS 组, ERAS 组 30 天再入院的发生率也显著降低。 结论: 本研究结果表明,ERAS 方案可加速 RC 患者的康复,降低术后并发症发生率,缩短 LOS, 在 RC 领域是安全可行的。本研究提供了来自 FUSCC 的经验,以进一步优化膀胱癌患者的 ERAS 方案。

展开更多

EJSO

研究方向:医学-外科
IF:4.424
IF值的bai意思是影响因子。是汤森路透(duThomson Reuters)出品的期刊引证报告zhi(Journal Citation Reports,JCR)中的一项数据。 影响因子dao目前的计算方法是:IF=C/(M+N)。以2017年IF的计算为例,M为该期刊2015年发表的文章数量,N为该期刊2016年发表的文章数量,C为该期刊2015和2016年两年发表的文章在2017年这一年被引用的
出版周期: ENGLAND
中科院分区:Q4 来稿接收率:约 % 审稿周期:偏慢,4-8周&来源Elsevier官网:平均7.6周
5.50%
YES
1985
0748-7983
出版地区: CiteScore:

我们的服务

SCI发表服务

资深医学编辑团队 ,全程协助发表无忧!>

中文期刊服务

资深医学编辑团队 ,全程协助发表无忧!>

临床科研服务

资深医学编辑团队 ,全程协助发表无忧!>

了解更多服务>
图片报名

EJSO 期刊简介

英文简介:

Surgical Oncology has finally come of age and EJSO continues to play a major role in dissemination of information and knowledge relating to this surgical specialty. Published eight times a year, it presents original articles and state-of-the-art reviews of immediate interest to surgical oncologists. In addition, papers are published on chemotherapy, radiotherapy, epidemiology and pathology of cancer. The articles published also reflect the importance of communication between the laboratory and the clinician. Features Include: Clinical Trials Section Clinical Debate Section Early 'fast-track' publication Regular Reviews Education Section Research Areas Include: Epidemiology and preventive aspects of oncology Diagnosis, including imaging All aspects of therapy, including radiotherapy and chemotherapy Application of new equipment to surgical and clinical oncology Methods of assessing results of treatment Case reports that advance clinical and pathological knowledge Computing in relation to oncology EJSO is abstracted/indexed by: Index Medicus; EMBASE; ASCA; Science Citation Index.

展开
中文简介

外科肿瘤学终于成熟了,EJSO继续在传播与该外科相关的信息和知识方面发挥着重要作用。每年出版八次,向外科肿瘤学家提供最新的文章和最新的评论。此外,论文还发表在化疗、放疗、流行病学和癌症病理学方面。发表的文章也反映了实验室和临床医生之间交流的重要性。特点包括:临床试验部分临床辩论部分早期“快速通道”出版物定期回顾教育部分研究领域包括:流行病学和肿瘤诊断预防方面,包括影像学治疗的各个方面,包括放射治疗和化疗新设备在外科和临床中的应用。肿瘤学评估肿瘤治疗病例报告结果的方法,推进了与肿瘤学EJSO相关的临床和病理学知识计算,其摘要/索引方法为:索引Medicus;EMBASE;ASCA;科学引文索引。

展开
qkw36015
点击复制微信号

EJSO期刊中科院评价数据

最新中科院JCR分区

大类(学科) 小类(学科) 学科排名
医学 ONCOLOGY(肿瘤学) 3区
SURGERY(外科学) 2区
87/223
24/200

最新公布的期刊年发文量

年度总发文量 年度论文发表量 年度综述发表量
278 220 58

总被引频次: 8540

特征因子: 0.016660

近年影响因子趋势图

EJSO期刊CiteScore评价数据

最新CiteScoere值

=

引文计数(2018)

文献(2015-2017)

=

次引用

篇文献

文献总数(2014-2016):

被引比率: %

SJR:
SCLmago期刊等级衡量经过加权后的期刊受引用次数,引用次数的加权值由施引期刊的学科领域和声望(SJR)决定。
SNIP:
每篇文章中来源出版物的标准化影响将实际受引用情况对照期刊所属学科领域中预期的受引用情况进行衡量。
图片报名

CiteScore排名

序号 类别(学科) 排名 百分位

CiteScore趋势图

Scopus涵盖范围

EJSO期刊常见问题

暂无相关内容~
图片报名

相关期刊

发表一篇

需要多少钱